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Background: Unspecific symptoms often proceed a serious chronic disease condition long before the onset of the
disease. The role of an unspecific premonitory symptom (UPMS) pattern as premonitory signs of subsequent type 2
diabetes mellitus (T2DM) diagnosis independent of established cardio-metabolic risk factors is unclear and therefore
was examined in the present study.
Methods: The study population consisted of 10,566 participants aged 25–74 years at baseline drawn from the
population-based MONICA/KORA Cohort Study conducted in 1984-2009 in the Augsburg region (Germany).
Unspecific premonitory symptoms were assessed following the Somatic Symptom Scale-8 (SSS-8). The impact of
the score on T2DM risk within a mean follow-up time of 16 years was estimated by Cox regression.
Results: Within follow-up, 974 newly diagnosed T2DM cases were observed. The risk for T2DM increased by a
hazard ratio (HR) of 1.03 (95% CI 1.01-1.04, p value < 0.001) for a one unit increase of the UPMS score in a Cox
model adjusted for age, sex and survey. Additional adjustment for cardio-metabolic risk factors attenuated this
effect (HR = 1.02) but significance remained (p value = 0.01).
Conclusions: Suffering from an elevated burden of unspecific somatic symptoms is associated with T2DM long
before the onset and independent of established cardio-metabolic risk factors. Further research is needed to obtain
insight in potential underlying pathophysiological mechanisms.
Keywords: Cohort study, General population, Type 2 diabetes mellitus, Unspecific premonitory symptom patternBackground
An unspecific premonitory symptom (UPMS) pattern is
often seen in clinical practice as a prodromal sign of a
serious chronic disease condition long before the onset
of the disease. In case of an acute coronary syndrome, it
is well established that symptoms of unusual fatigue,
dizziness and vital exhaustion several months preceding
the event are very common [1,2]. However, an UPMS* Correspondence: ladwig@helmholtz-muenchen.de
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unless otherwise stated.pattern is also prevalent among subjects with no obvious
medical disorder [3]. Often, the medical significance of
the symptoms that are reported is unclear and an assign-
ment to a specific underlying disease is not always
possible [4,5]. In primary care, about half of the symp-
toms reported may be functional [6].
One major obstacle in the treatment of type 2 diabetes
mellitus (T2DM) is the well acknowledged fact that the
disease often remains undiagnosed for many years. A pro-
gressive decrease in ß-cell insulin secretion begins as early
as 12 years before diagnosis [7]. The onset of an increased
risk to develop micro- and macrovascular complications
also predates the point of clinical recognition by several
years [8,9] such that at diagnosis approximately 50% ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Baumert et al. BMC Endocrine Disorders 2014, 14:87 Page 2 of 9
http://www.biomedcentral.com/1472-6823/14/87patients have evidence of diabetes-related complications
[9,10]. However, the disease condition often remains being
viewed as asymptomatic in its early stages [11].
Premonitory signs before the onset of T2DM are mainly
related to hyperglycaemic states and acute metabolic dis-
turbances. Here, polyuria, polydipsia, weight loss, some-
times along with polyphagia, and blurred vision are
acknowledged as key symptoms. Subjects suffering from
these symptoms are viewed being at increased risk to ex-
perience the onset of T2DM [12]. The American Diabetes
Association (ADA) and the International Diabetes Feder-
ation (IDF) developed lists of symptoms [13,14] which are
recommended to call for immediate medical attention if
individuals experience one or more of these symptoms.
Although unusual fatigue and irritability as unspecific
mood changes are also taken into consideration, to the
best of our knowledge, no investigation to date has studied
whether a more unspecific symptom picture beyond the
known premonitory signs of an acute hyperglycaemia is
indicative for the development of T2DM several years be-
fore the point of clinical recognition.
Thus, the aim of the present study was to assess the
role of an unspecified premonitory pattern on newly di-
agnosed T2DM in a large prospective study including
men and women from the general population, independ-
ent of established cardio-metabolic lifestyle and mental
health related risk factors. Furthermore, we analysed




The data of the present study were drawn from the
population-based MONICA/KORA Augsburg cohort
study based on three independent surveys (S1, S2, S3) car-
ried out from 1984 to 1995 in the Augsburg region, south-
ern Germany, including 13,426 participants aged 25-74
years [15]. The MONICA (MONItoring of trends and
determinants in CArdiovascular disease) Augsburg project
was part of the multinational WHO MONICA project
[16]. The incidence of type 2 diabetes was determined
within the framework of the KORA (Cooperative Health
Research in the Region of Augsburg) platform by follow-
up examinations until 2009 [17]. The study followed the
declaration of Helsinki and was approved by the local
authorities: The MONICA surveys S1, S2 and S3 with the
baseline examination were approved by the data protec-
tion commission following the rules at the time of the
examinations (1984/85, 1989/90 and 1994/95); the follow-
up examinations within the KORA framework afterwards
were approved by the ethics committee of the Bavarian
Medical Association (“Bayerische Landesärztekammer”).
Written informed consent was obtained from each study
participant.Study population
Among the whole MONICA/KORA Augsburg cohort
study (n = 13,426), psychosocial data using a self-
administered questionnaire were assessed in 12,886
participants. The psychosocial data set extended the
MONICA core design and followed recommendations
given by the MONICA steering committee [18]. Among
them, participants with a self-reported history of diabetes
at baseline examination (n = 535), missing information
on newly diagnosed type 2 diabetes (n = 626), unspecific
premonitory symptom patterns (n = 840), or any other
variable described below (n = 319) were excluded from
the present analyses leading to a study population of
10,566 participants (5,448 men, 5,118 women) with a
mean age of 46.7 years (standard deviation (SD) 13.2)
ranging from 25 to 74 years at baseline. The mean
follow-up time for the present study population was
15.6 years with a standard deviation of 6.2 and a range
from 0.1 to 25.2 years in 164,963 person-years.
Definition of an unspecified premonitory symptom
pattern
The unspecified premonitory symptom pattern was
assessed at the baseline examination by creating a score
based on similar items of the recently developed 8-item
Somatic Symptom Scale-8 (SSS-8) which shows high re-
liability and validity [19,20]. The following eight items
from the von Zerssen symptom checklist [21] were used
to build our modified SSS-8: stomach or bowel pain,
back pain, pain in the joints, headaches or pressure in
the head, temporary shortness of breath, dizziness, feel-
ing tired and insomnia. Each item was measured on a
four-point scale ranging from 0 (not present) to 3
(strong) leading to an UPMS score ranging from 0 to 24
(the items of SSS-8 are measured on a five-point scale)
which was approximately normal distributed. Cronbach’s
α was estimated as 0.75 in the present study indicating a
good reliability. For descriptive purposes, the UPMS
score was classified into three categories using tertiles as
cut-off points.
Definition of newly diagnosed type 2 diabetes
A written follow-up questionnaire was sent to all partici-
pants of the three baseline surveys in 1997/1998, in
2002/2003 and in 2008/2009. Furthermore, all subjects
who participated in the first survey were invited to par-
ticipate in a follow-up examination conducted in 1987/
1988. Self-reported newly diagnosed cases of diabetes
mellitus and the date of diagnosis were validated by hos-
pital records or by contacting the proband’s treating
physician. Furthermore, the hospital records of those de-
ceased during the follow-up period without a diagnosis
of type 2 diabetes mellitus at baseline were also exam-
ined and/or their last treating physicians were contacted.
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for a history concerning diabetes and if a person had
suffered from diabetes, the type of diabetes and the date
of diagnosis were ascertained. If a participant was not
found in any of the medical records and if no informa-
tion from the last treating physician could be obtained,
the participant was excluded from analysis [22].
Definition of cardio-metabolic risk factors
Standardized face-to-face interviews were conducted at
baseline examination by trained medical staff (mainly
nurses) to assess information concerning sociodemo-
graphic, lifestyle and clinical characteristics. Additionally,
participants underwent an extensive standardised medical
examination including collection of a non-fasting venous
blood sample. All assessment procedures followed the
standardized protocol of the WHO MONICA project [16]
and have been described in detail elsewhere [23,24].
Low educational level was defined as having less than
12 years of schooling. Parental history of diabetes was
classified as ‘yes’ if the participant reported that at least
one of the parents had diabetes, ‘no’ if no diabetes for both
parents was reported and ‘unknown’ in all other cases.
Current smoking was defined as currently smoking at
least one cigarette per day or smoking occasionally. Alco-
hol consumption was classified into three categories:
none (0 g/day), moderate (0.1-39.9 g/day for men and
0.1-19.9 g/day for women) and high (≥40.0 g/day for men
and ≥20.0 g/day for women). To assess physical activity,
participants were classified as ‘active’ during leisure time
if they regularly participated in sports for at least 1 hour
per week; otherwise they were considered ‘inactive’.
Actual hypertension was defined as blood pressure ≥140/
90 mmHg and/or current use of hypertensive medication,
given that the subjects were aware of being hypertensive.
Total cholesterol (TC) and high density lipoprotein choles-
terol (HDL-C) were measured in mg/dl by enzymatic
methods (CHOD-PAP, Boehringer Mannheim, Germany).
The TC/HDL-C ratio was dichotomized into two groups
(<5, ≥5). Body mass index (BMI) was calculated as weight
in kilograms divided by height in meters squared, both
assessed in a medical examination. For descriptive
purposes, BMI was categorized in three groups (<25,
25 - <30, ≥30 kg/m2).
Depressed mood was examined by the “Depression
and Exhaustion” (DEEX) scale consisting of eight items
drawn from the von Zerssen affective symptom check
list [25] and using the upper tertile as cut-off point
(<11, ≥11). Depressed mood was only available in
10,554 participants.
Statistical analyses
Mean differences of the UPMS score by categorized vari-
ables were assessed by the t or F test.Cox regression with different grades of adjustments
for cardio-metabolic risk factors was applied to assess
the association of the UPMS score with the risk for
newly diagnosed type 2 diabetes. The UPMS score was
included in the Cox regression models as a continuous
variable using a fractional polynomials (FP) transform-
ation approach to find the appropriate score-diabetes
risk relation [26]. Adjustments were made for age, sex
and survey (model 1) and additionally for the risk
factors educational level, and parental history of dia-
betes (model 2), smoking, alcohol consumption and
physical inactivity (model 3), actual hypertension and
TC/HDL-C (model 4) and BMI (model 5).
The predictive ability of the Cox models to assess T2DM
risk was estimated by the AUC (area under the curve), the
IDI (integrated discrimination improvement) and the NRI
(net reclassification improvement) following the approach
of Pencina et al. [27] as measurements for accuracy of
T2DM risk prediction using the SAS macro RECLASSIFI-
CATION_PHREG developed by Mühlenbruch [28].
To assess the robustness of the findings revealed by
the Cox regression models, we performed sensitivity and
interaction analyses. First, since it cannot be excluded
that a UPMS may indicate early signs of a type 2 dia-
betes disease, we repeated the Cox regression analyses
by excluding participants with a follow-up time less than
two years (n = 151). Second, to evaluate rather the short
term impact of UPSM on T2DM risk, we performed a
Cox regression assessing the risk to develop T2DM
within 5 years. Third, potential modifications between
the UPMS score and age, sex or any of the risk factors
stated above were tested by adding the respective inter-
action term to the fully-adjusted model 5. To account
for multiple testing in the interaction analyses, the sig-
nificance level was corrected by the Bonferroni method
leading to a significance level of 0.005 (as ten variables
were under concern).
For all statistical analyses, a p value <0.05 was considered
to be statistically significant, except for the interaction
analyses (p <0.005 following Bonferroni correction). SAS
Version 9.2 for Windows (SAS Institute, Cary, NC) was
used for all statistical analyses; for applying the FP trans-
formation approach, the SAS macro MFP8 was used [26].
The analysis and the description in this article
follow the STROBE guidelines for observational cohort
studies [29].
Results
Description of study population
A total of 974 newly diagnosed T2DM cases (599 men‚
375 women) were observed within a mean follow-up
time of 15.6 years indicating 16 newly diagnosed T2DM
cases in 1,000 person-years. The (unadjusted) distribu-
tions of age, sex and the cardio-metabolic risk factors as
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T2DM cases and non-cases. Except for smoking and alco-
hol consumption, the association between classic risk fac-
tors with T2DM were highly significant (p value <0.001)
with cases being older, more often male and low educated,
having higher BMI and TC/HDL-C values, being more
frequently physical inactive, having more often a parental
history of diabetes and hypertension. Moreover, the mean
UPMS score was higher for cases than for non-cases (8.52
versus 7.69).
Overall, the UPMS score ranged from 0 to 24 with an
average of 7.76 (SD 4.31). A minority of 2.3% (n = 242)
of all participants did not report any somatic complaint;
for about 10% of the participants, the score was 13 or
higher. Figure 1 shows the distribution of the UPMS
score by age class separately for men and women. In all
age classes, the mean UPMS score was significantly
higher in women than in men (p values <0.001). In both
sexes, an increasing UPMS score by growing age was ob-
served until age class 55-64 years where a plateau was
reached and the UPMS score remained rather stable for
participants aged 65-74 compared to 55-64 years.
Table 2 gives the mean UPMS score (with standard de-
viation) for each cardio-metabolic risk factor. Compared
to their respective counterparts, the mean score was sig-
nificantly higher in women, in older age groups, in lessTable 1 Age, sex and risk factor distribution at baseline
in newly diagnosed T2DM cases and non-cases
(n = 10,566)
T2DM cases T2DM non-cases P value
(n = 974) (n = 9,592)
Age (in years)* 52.9 (10.8) 46.1 (13.2) < 0.001
Male sex 61.5 50.6 < 0.001
Low educational level 80.9 70.1 < 0.001









Physical inactivity 66.0 55.8 < 0.001
Actual hypertension 59.8 33.5 < 0.001
TC/HDL-C* 5.49 (2.16) 4.39 (1.77) < 0.001
BMI (in kg/m2)* 29.7 (4.5) 26.1 (3.9) < 0.001
UPMS score* 8.52 (4.62) 7.69 (4.27) < 0.001
*mean (standard deviation).
BMI: Body mass index; TC/HDL-C: Total cholesterol/High density lipoprotein
cholesterol; UPMS: Unspecific premonitory symptom.educated and obese subjects, in non-smokers and non-
alcohol consumers and in physically inactive subjects, in
subjects with known or unknown parental history of dia-
betes and hypertension (p values <0.001).
The frequency of newly diagnosed T2DM in the
UPMS score tertiles were estimated by Kaplan-Meier
curves (Figure 2) indicating higher risks for T2DM in
the upper tertile (T3) compared to the lower and middle
tertiles (T1 and T2).
Association of the UPMS score with the risk for newly
diagnosed T2DM
Cox regression analyses using FP transformation revealed
a linear relation between the UPMS score and newly di-
agnosed T2DM risk in all models. Adjusted for age, sex
and survey, the risk for newly diagnosed T2DM increased
with a hazard ratio (HR) of 1.03 (95% CI 1.01-1.04,
p <0.001) per each UPMS score unit increase as shown in
Table 3. Additional adjustments for cardio-metabolic risk
factors attenuated this effect but significance remained.
The fully-adjusted model 5 estimated a HR of 1.02 (95%
1.01-1.04), p value = 0.01); calculations based on this
estimation revealed for example that the T2DM risk of
an individual with a score at the 75th percentile (=11)
compared to an individual with a score value at the 25th
percentile (=5) increased by 12%.
An analysis of the predictive ability of UPMS for
T2DM risk indicated very low improvement by adding
the UPMS score. Regarding T2DM risk within 10 years,
the AUC was 0.7995 in the model without and 0.7999
with the UPSM score in the model adjusted for all car-
diovascular risk factors (model 5). Similar findings were
observed by estimating IDI and NRI.
Sensitivity and interaction analyses
Excluding participants with a follow-up time of less than
two years (71 cases, 80 non-cases) revealed comparable
hazard ratios (model 1: HR: 1.03, 95% CI: 1.01-1.04,
model 5: HR: 1.02, 95% CI: 1.00-1.03) and p values
(model 1: <0.001 and model 5: 0.02) for the UPMS score.
Assessing the risk to develop T2DM within five years
led to similar and significant findings with a HR of 1.04
(95% CI 1.01-1.07, p value 0.006) in model 1 and a HR
of 1.03 (95% CI 1.00-1.06, p value 0.03) in model 5.
Including additionally depressed mood in the fully-
adjusted model decreased the hazard ratio of the UPMS
score to 1.01 (0.99-1.03, p value 0.18). Stratified analyses
estimated for the first model for the score a hazard ratio
of 1.02 (95% CI 1.00-1.04, p value 0.10) in the non-
depressed mood group (n = 6,769) and 1.06 (95% CI
1.03-1.09, p value <0.001) in the group with depressed
mood (n = 3,785).
Regarding potential interactions, we could not detect
any significant modification of this effect by age, sex or
Figure 1 Distribution of UPMS score by age class in men and women.
Table 2 Risk factors and mean UPMS score (n =10,566)
Risk factor Category UPMS score P value
Mean (standard
deviation)
All 7.76 (4.31) -
Educational level Low 8.24 (4.40) < 0.001
High 6.59 (3.83)
Parental history of diabetes No 7.48 (4.20) < 0.001
Yes 8.13 (4.35)
Unknown 8.38 (4.54)
Current smoker No 7.91 (4.28) < 0.001
Yes 7.37 (4.36)
Alcohol consumption No 8.46 (4.58) < 0.001
Moderate 7.52 (4.15)
High 7.44 (4.20)
Physical inactivity No 6.99 (4.05) < 0.001
Yes 8.35 (4.40)
Actual hypertension No 7.59 (4.19) < 0.001
Yes 8.07 (4.49)
TC/HDL-C < 5 7.81 (4.24) 0.14
≥5 7.67 (4.47)
BMI (kg/m2) < 25 7.43 (4.13) < 0.001
25- <30 7.80 (4.34)
≥30 8.45 (4.55)
BMI: Body mass index; TC/HDL-C: Total cholesterol/High density lipoprotein
cholesterol; UPMS: Unspecific premonitory symptom.
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for multiple testing. However, suggestive interactions
were found for TC/HDL-C and BMI with a stronger ef-
fect of the UPMS score on T2DM risk in participants
with a higher compared to a lower TC/HDL-C (p value
0.03) and in lower BMI compared to higher BMI values
(p value 0.04) in fully-adjusted models.
Discussion
Overall findings
In this long-term prospective population based study, we
found that apparently healthy participants reporting a dis-
tinct pattern of unspecific somatic symptoms at baseline
experienced a substantial increase in newly diagnosed
T2DM risk over the observation period, even after con-
trolling for classical cardio-metabolic risk factors. An un-
specific premonitory symptom (UPMS) pattern has been
identified as a premonitory prodromal sign of a serious
chronic disease condition long before the onset of the
disease particularly in acute coronary syndromes [1,2] –
however, to the best of our knowledge – this has not been
shown before in the case of the onset of a T2DM.
The somatic symptoms which have been captured by
the 8-item Somatic Symptom Scale-8 (SSS-8) in the
present investigation have only a negligible overlap with
the symptoms acknowledged as being “classic” early dia-
betes signs by the ADA and IDF [13,14]. The clinical
presentation of early diabetes symptoms is usually related
to polyuria, polydipsia, weight loss, blurred vision and
Figure 2 Frequency of newly diagnosed of T2DM by UPMS score tertiles (T1, T2, T3) estimated by Kaplan-Meier curves.
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pattern assessed in the present investigation compiles the
following symptoms: stomach or bowel pain, back pain,
pain in the joints, headaches or pressure in the head,
temporary shortness of breath, dizziness, feeling tired
and insomnia. The present investigation gives indications
to consider this particular array of somatic symptoms asTable 3 Association of the UPMS score with risk for newly
diagnosed type 2 diabetes estimated by Cox regression:




Model 1: Age, sex and survey 1.03 < 0.001
(1.01-1.04)
Model 2: M1 + educational level and
parental history of diabetes
1.02 0.001
(1.01-1.04)




Model 4: M3 + hypertension, TC/HDL-C 1.02 0.005
(1.01-1.04)
Model 5: M4 + BMI 1.02 0.01
(1.01-1.04)
HR: Hazard ratio; CI: Confidence interval; UPMS: Unspecific premonitory
symptom.premonitory signs of T2DM within a long time window
before clinical recognition.
Pathophysiological explanations
Although an exact evaluation of the pathophysiological
pathways is beyond the scope of the present study, we
assume three major possible explanations for underlying
mechanisms that may lead to an association between the
UPSM score and newly diagnosed T2DM risk in our
study population.
First, one may suspect that an elevated burden of un-
specific premonitory symptoms is a prodromal sign of
an already existing but still undiagnosed T2D. This is
not unlikely as it is well established that the risk of
T2DM patients developing microvascular complications
often predates the point of clinical recognition by several
years [9,10]. However, in a sensitivity analysis excluding
subjects with a follow-up time of less than two years, the
impact of the UPMS score on newly diagnosed T2DM
risk remained stable with very similar hazard ratios
which renders this explanation as unlikely.
Second, we observed in the present investigation that
subjects with high UPMS scores were more likely to ex-
perience hypertension, obesity and physical inactivity. It is
well established that subjects at risk to develop T2DM are
likely to cluster cardiovascular risk factors [9] with subse-
quent higher risks of the onset of CVD and diabetes-
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UPMS score on newly diagnosed T2DM risk remained
significant independent from the cardio-metabolic risk
profile indicating that an elevated UPMS had its own
contribution to T2DM risk assessment. The association
of UPMS and CVD risk factors not only reflects an
unfavourable state of health contributing to the onset of
diabetes in the future but also points to a sustained
subclinical heightened inflammatory activity as a com-
mon link of these risk conditions. Indeed, inflammatory
activity has been shown for untreated hypertension
[30-32], obesity [31,33] and physical inactivity [34,35].
Inflammation, in turn, can trigger behavioural conse-
quences which resemble symptoms which are at least in
part captured by the SSS-8 (e.g. dizziness, feeling tired
and insomnia) [36,37].
Third, the increased preoccupation and awareness of
bodily symptoms patterns is likely to cause chronic stress
particularly as the lack of a “medical explanation” for un-
specific symptoms often leads to feelings of uncertainty, to
rejection from the side of the physician with subsequent
symptom amplification and persistence of symptoms – yet
without any prospects of successful treatment. Further-
more, there is a large body of evidence suggesting that the
sustained experience of a high somatic symptom burden
is also strongly associated with adverse mental health
related conditions such as depression, anxiety, sleeping
disturbance or low self-perceived health [38-40]. Perman-
ent psychological distress and consequently in chronic
stress conditions has been shown to contribute to adverse
metabolic dysregulations [41,42] and furthermore to in-
creased T2DM risk [22,43-46]. Thus, our findings may be
explained partly by the relation between elevated unspe-
cific symptom burden and adverse chronic stress condi-
tions. Particularly, depressed mood has been proven as a
risk marker for the onset of T2DM. Mezuk et al. (2008)
performed a meta-analysis including 13 studies with 6,916
incident T2DM cases and revealed that depression in-
creased the risk for T2DM by 60% [47]. The association
between depression and insulin resistance was shown to
be small, however robust [48]. In the present investigation,
analyses stratified for depressed mood revealed rather
similar risk estimates for the UPSM score in participants
without and with depressed mood (HR 1.02 and 1.06) in a
model adjusted for age, sex and survey. However, when
depressed mood was added to the fully-adjusted model in
the total sample, the effect of the UPMS score decreased
to 1.01 and significance vanished (p value 0.18). Also de-
pressed mood did not reach significance in this model
(p value 0.15). As both variables were highly correlated,
inclusion of the score and depressed may over-adjust the
Cox model. Therefore, as a practical consequence, when
dealing with patients potentially at risk, physicians may
assess the symptom count of premonitory signs or mayscreen for depressed mood – the findings will be most
likely very similar.
Strengths and Limitations
The strengths of the present study are the prospective
design, the large sample size based on a random sample
drawn from the general population and the availability of
a large set of risk factors which were scrutinized by stan-
dardized and quality-controlled assessments. Addition-
ally, as far as we know, this is the first prospective study
investigating the association of an unspecific premonitory
symptom pattern with newly diagnosed type 2 diabetes
risk in a population-based sample. The distribution of
risk factors at baseline in newly diagnosed T2DM cases
and non-cases as shown in Table 1 as well as the impact
of risk factors on T2DM risk as estimated by the Cox re-
gression analyses (data not shown) were as expected and
comparable to previous studies.
One major limitation is that we cannot assess whether
the symptom pattern was caused by specific chronic dis-
ease conditions. If a strong relation between unspecific
symptom patterns and chronic diseases is assumed, a
constant increase of symptom reporting by growing age
would be expected (as the prevalence of chronic diseases
increase by age). However, symptom reporting remained
stable after in participants aged 55 years or older as
shown in Figure 1 for our study population indicating
that a causation of symptom patterns mainly by chronic
diseases may not be assumed. Moreover, our findings
may be affected by other incident diseases within the
follow-up period which could not be assessed in the
present study population. The improvement in predictive
ability for T2DM risk was rather low when the UPMS
score was added to the cardiovascular risk factors in the
Cox regression (model 5). Nevertheless we think that our
findings give important indications to consider a particu-
lar array of somatic symptoms as premonitory signs of
T2DM within a long time window before clinical recog-
nition. The AUC in the present study were around 0.80
which was in the range of AUCs (0.76 to 0.81) estimated
in a recently published validation study of 12 existing
T2DM prediction models [49]. Furthermore, it cannot
be excluded that participants reporting no history of
diabetes at baseline examination suffer from an undiag-
nosed diabetes or a prediabetic state. Finally, UPMS is cur-
rently not an inherent part of data collection in routine
setting. However, the documentation of a UPSM pattern
consisting of several unspecific somatic symptoms would
be easy to assess in routine settings with limited time costs.
Conclusions
This prospective population-based study found a sub-
stantial association of an elevated burden of unspecific
premonitory symptoms with T2DM long before the onset
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tors. Further research is needed to confirm or refute our
findings and to obtain insight in potential underlying
pathophysiological mechanisms.
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